Flerie AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FLERIE.ST research report →
Companywww.flerie.com
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. It seeks to invest in biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, United States and Israel.
- CEO
- Ted Fjallman
- IPO
- 2024
- Employees
- 8
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $2.23B
- P/E
- -3.41
- P/S
- -92.15
- P/B
- 0.53
- EV/EBITDA
- -2.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 192.98%
- Op Margin
- 2733.06%
- Net Margin
- 2345.04%
- ROE
- -15.05%
- ROIC
- -17.99%
Growth & Income
- Revenue
- $8.80M · 8700.00%
- Net Income
- $-756,900,000 · -231.97%
- EPS
- $-9.71 · -199.69%
- Op Income
- $-782,100,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $41.74
- 52W Low
- $23.10
- 50D MA
- $26.66
- 200D MA
- $32.31
- Beta
- -0.13
- Avg Volume
- 62.15K
Get TickerSpark's AI analysis on FLERIE.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FLERIE.ST Coverage
We haven't published any research on FLERIE.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FLERIE.ST Report →